C
Chunyan Song
Researcher at Genentech
Publications - 27
Citations - 732
Chunyan Song is an academic researcher from Genentech. The author has contributed to research in topics: Trastuzumab & Trastuzumab emtansine. The author has an hindex of 9, co-authored 16 publications receiving 531 citations.
Papers
More filters
Journal ArticleDOI
Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Sara A. Hurvitz,Luc Dirix,Judit Kocsis,Giulia Bianchi,Janice Lu,Jeferson Vinholes,Ellie Guardino,Chunyan Song,Barbara Tong,Vivian Ng,Yu Waye Chu,Edith A. Perez +11 more
TL;DR: First-line treatment with T-DM1 for patients with HER2-positive MBC provided a significant improvement in PFS, with a favorable safety profile, versus HT, in this randomized phase II study.
Journal ArticleDOI
Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
Sara A. Hurvitz,Miguel Martin,Kyung Hae Jung,Chiun-Sheng Huang,Nadia Harbeck,Vicente Valero,Daniil Stroyakovskiy,Hans Wildiers,Mario Campone,Jean Francois Boileau,Peter A. Fasching,Karen Afenjar,Gonzalo Spera,Vanesa Lopez-Valverde,Chunyan Song,Peter Trask,Thomas Boulet,Joseph A. Sparano,W. Fraser Symmans,Alastair M. Thompson,Dennis J. Slamon +20 more
TL;DR: Compared with TCH+P, T-DM1+P resulted in a higher risk of a EFS event owing to locoregional progression events before surgery, a similar risk of an IDFS event, fewer grade 3 or greater AEs during neoadjuvant treatment, and more AEs leading to treatment discontinuation during adjuvant treatment.
Journal ArticleDOI
616OPertuzumab (P) + trastuzumab (H) + chemotherapy (CT) for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (mGC/GEJC): Final analysis of a Phase III study (JACOB)
J. Tabernero,Paulo M. Hoff,Li Shen,A. Ohtsu,Manish A. Shah,K. Cheng,Chunyan Song,H. Wu,Jennifer Eng-Wong,Y-K. Kang +9 more
Journal ArticleDOI
Occurrence and outcome of de novo metastatic breast cancer by subtype in a large, diverse population.
Li Tao,Laura Chu,L. Wang,Lisa M. Moy,Melissa Brammer,Chunyan Song,Marjorie C. Green,Allison W. Kurian,Scarlett Lin Gomez,Scarlett Lin Gomez,Christina A. Clarke,Christina A. Clarke +11 more
TL;DR: De novo metastatic breast cancer was more likely to be HER2+.
Journal ArticleDOI
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
Eleftherios P. Mamounas,Michael Untch,Max S. Mano,C.-S. Huang,Charles E. Geyer,G. von Minckwitz,Norman Wolmark,Xavier Pivot,S. Kuemmel,Michael P. DiGiovanna,Bella Kaufman,Georg Kunz,Alison Conlin,J.C. Alcedo,T. Kuehn,Irene Wapnir,Andrea Fontana,John Hackmann,Jonathan Polikoff,Mahasti Saghatchian,Adam Brufsky,Youngsen Yang,Martina Zimovjanova,Thomas Boulet,H. Liu,D. Tesarowski,Lisa H. Lam,Chunyan Song,Melanie Smitt,Melanie Smitt,S. Loibl +30 more
TL;DR: The KATHERINE study as discussed by the authors showed that patients with residual invasive early breast cancer (EBC) after neoadjuvant chemotherapy (NACT) plus human epidermal growth factor receptor 2 (HER2)-targeted therapy had a 50% reduction in risk of recurrence or death with adjuvant trastuzumab emtansine (T-DM1) versus trastusumab.